Based on these results, the National Comprehensive Cancer Network (NCCN) guidelines recommend pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy for patients with NSCLC who have a high PD‐L1 tumor proportion score (TPS).6 This evidence concerns the gene CD274 and non-small cell lung carcinoma.